{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T02:19:18Z","timestamp":1723083558333},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Ministry of Culture and Science of Japan","award":["20590810"],"award-info":[{"award-number":["20590810"]}]},{"name":"Ministry of Culture and Science of Japan","award":["23591017"],"award-info":[{"award-number":["23591017"]}]},{"name":"Ministry of Culture and Science of Japan","award":["24591020"],"award-info":[{"award-number":["24591020"]}]},{"name":"Ministry of Culture and Science of Japan","award":["17877850"],"award-info":[{"award-number":["17877850"]}]},{"name":"Ministry of Culture and Science of Japan","award":["17K09468"],"award-info":[{"award-number":["17K09468"]}]},{"name":"Ministry of Culture and Science of Japan","award":["15K09052"],"award-info":[{"award-number":["15K09052"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder recognized as a novel clinical entity with either synchronous or metachronous multiorgan involvement. Autoimmune pancreatitis (AIP) is classified into two types: type 1 AIP as a pancreatic manifestation of IgG4-RD and type 2 AIP with granulocytic epithelial lesion and occasional association with ulcerative colitis. Although the pathogenic mechanism still remains unclear, possible multipathogenic factors such as genetic factors, disease-specific or related antigens, and abnormal innate or adaptive immunity may be involved in the development of IgG4-RD. Many immunocytes including M2 macrophages, plasmablasts, B cells, and T-cells (Th2-CD4+T, follicular helper T-cells, and CD4+SLAMF7+cytotoxic T-cells) play important roles in the pathogenesis. Conventional induction and maintenance therapies with glucocorticoid or rituximab are recommended in all symptomatic patients with active IgG4-RD. In those at risk for irreversible damage in any organs, this should be done urgently, regardless of symptoms. As no randomized clinical trials other than glucocorticoid maintenance therapy for type 1 AIP have been performed, the comprehensive management for IgG4-RD has not been established yet. Targeted treatment approaches against the plasmablast to B cell lineage and the CD4+ SLAMF7+ cytotoxic T-cell seem to be promising for the future-directed treatment.<\/jats:p>","DOI":"10.1093\/mr\/roac054","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T20:14:48Z","timestamp":1656015288000},"page":"237-241","source":"Crossref","is-referenced-by-count":4,"title":["Recent progress on the treatment of type 1 autoimmune pancreatitis and IgG4-related disease"],"prefix":"10.1093","volume":"33","author":[{"given":"Kazuichi","family":"Okazaki","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Kansai Medical University Kori Hospital , Neyagawa, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Ikeura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kansai Medical University , Hirakata, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi University , Nankoku, Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/BF02285209","article-title":"Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis","volume":"40","author":"Yoshida","year":"1995","journal-title":"Dig Dis Sci"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0046-8177(91)90087-6","article-title":"Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas","volume":"22","author":"Kawaguchi","year":"1991","journal-title":"Hum Pathol"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.autrev.2014.01.010","article-title":"Diagnosis and classification of autoimmune pancreatitis","volume":"13","author":"Okazaki","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-011-0508-6","article-title":"A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details","volume":"22","author":"Umehara","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/art.34593","article-title":"Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations","volume":"64","author":"Stone","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MPA.0b013e3182142fd2","article-title":"International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the international association of pancreatology","volume":"40","author":"Shimosegawa","year":"2011","journal-title":"Pancreas"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1056\/NEJM200103083441005","article-title":"High serum IgG4 concentrations in patients with sclerosing pancreatitis","volume":"344","author":"Hamano","year":"2001","journal-title":"N Engl J Med"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/MPA.0000000000000382","article-title":"Autoimmune pancreatitis: the past, present, and future","volume":"44","author":"Okazaki","year":"2015","journal-title":"Pancreas"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaci.2015.12.1330","article-title":"Clonal expansion of CD4 cytotoxic T lymphocytes in patients with IgG-related disease","volume":"138","author":"Mattoo","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/all.12342","article-title":"Circulating Th2 memory cells in IgG4-related disease are restricted to a defined subset of subjects with atopy","volume":"69","author":"Mattoo","year":"2014","journal-title":"Allergy"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/art.40469","article-title":"A CD8alpha- subset of CD4+SLAMF7+ cytotoxic T cells is expanded in patients with IgG4-related disease and decreases following glucocorticoid treatment","volume":"70","author":"Della-Torre","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","DOI":"10.1186\/s12865-020-00361-0","article-title":"Association of circulating SLAMF7(+)Tfh1 cells with IgG4 levels in patients with IgG4-related disease","volume":"21","author":"Higashioka","year":"2020","journal-title":"BMC Immunol"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.27435","article-title":"Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease","volume":"62","author":"Khosroshahi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/gutjnl-2012-302886","article-title":"Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience","volume":"62","author":"Hart","year":"2013","journal-title":"Gut"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of IgG4-related disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00535-016-1302-1","article-title":"Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: a long-term Japanese multicenter analysis of 510 patients","volume":"52","author":"Kubota","year":"2017","journal-title":"J Gastroenterol"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28405-x","article-title":"Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study","volume":"8","author":"Shirakashi","year":"2018","journal-title":"Sci Rep"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pan.2016.12.003","article-title":"International consensus for the treatment of autoimmune pancreatitis","volume":"17","author":"Okazaki","year":"2017","journal-title":"Pancreatology"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00535-022-01857-9","article-title":"Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020","volume":"57","author":"Okazaki","year":"2022","journal-title":"J Gastroenterol"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pan.2016.03.017","article-title":"Obstructive jaundice in autoimmune pancreatitis can be safely treated with corticosteroids alone without biliary stenting","volume":"16","author":"Bi","year":"2016","journal-title":"Pancreatology"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2016-312049","article-title":"Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis","volume":"66","author":"Masamune","year":"2017","journal-title":"Gut"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40266-018-0534-6","article-title":"IgG4-related disease: beyond glucocorticoids","volume":"35","author":"Akiyama","year":"2018","journal-title":"Drugs Aging"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00535-021-01817-9","article-title":"The clinical efficacy of azathioprine as maintenance treatment for autoimmune pancreatitis: a systematic review and meta-analysis","volume":"56","author":"Masaki","year":"2021","journal-title":"J Gastroenterol"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/gutjnl-2012-303635","article-title":"Autoimmune pancreatitis in MRL\/Mp mice is a T cell-mediated disease responsive to cyclosporine A and rapamycin treatment","volume":"63","author":"Schwaiger","year":"2014","journal-title":"Gut"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0033-1345722","article-title":"Immunosuppression and HBV reactivation","volume":"33","author":"Shouval","year":"2013","journal-title":"Semin Liver Dis"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/MPA.0000000000001925","article-title":"Rituximab as maintenance therapy in type 1 autoimmune pancreatitis: an Italian experience","volume":"50","author":"De Marchi","year":"2021","journal-title":"Pancreas"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1080\/00365521.2021.1963837","article-title":"Efficacy and safety of rituximab in autoimmune pancreatitis type 1: our experiences and systematic review of the literature","volume":"56","author":"Nikolic","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"2023030304341837000_","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661196","article-title":"The role of B cells and B cell therapies in immune-mediated liver diseases","volume":"12","author":"Cargill","year":"2021","journal-title":"Front Immunol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac054\/44276614\/roac054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/2\/237\/49400609\/roac054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/2\/237\/49400609\/roac054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T17:22:52Z","timestamp":1700760172000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/2\/237\/6614624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,6,23]]},"published-print":{"date-parts":[[2023,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac054","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,6,23]]}}}